Has Russell Jayne, MD received payments from drug or device companies?

Yes. Drug and device makers reported $7,896 in general payments to Russell Jayne, MD across 32 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Russell Jayne, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Russell Jayne, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Russell Jayne, MD

Retina Specialist · Las Vegas, NVNPI 1689671687

Payments from drug & device makers

What this record shows

This record is dominated by other: $7,000 of the $7,896 with a category attached, or 88.6%. Optos, Inc. accounts for 89.0% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $7,132 and has fallen 97.3% since, to $192 in 2025.

$7,896in general payments, 2019–2025

Across 32 payments — averaging $246.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Optos, Inc.$7K
Genentech USA, Inc.$334
Amgen$122
Sandoz$115
Coherus Oncology, Inc.$81
Carl Zeiss Meditec, Inc.$70
plus $151 from 4 others

What the payments were for

Food & beverage$89611%
Other$7,00089%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Optos, Inc.	2	$7,025
Genentech USA, Inc.	15	$334
Amgen	1	$122
Sandoz	5	$115
Coherus Oncology, Inc.	3	$81
Carl Zeiss Meditec, Inc.	1	$70
Iridex Corporation	1	$54
Astellas Pharma US Inc	2	$54
Novartis	1	$22
Biogen	1	$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few retina specialist providers in Nevadato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$703,609

Medicare patients

471

Services billed

4,885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	72	$4,402
Brimonidine Tartrate	14	$710

Paid to pharmacies, not to this prescriber.

Other retina specialist in Las Vegas

George ParLas Vegas$110K
Chris WuLas Vegas$11K
Charles CalvoLas Vegas$2K
Alec AmramLas Vegas$1K
Tyson WardLas Vegas$1K
Greggory GahnReno$15K
Spencer FullerReno$6K
William StevensonReno$5K
John GunnHenderson$1K
Zachary BodnarHenderson$724

See the full list for Nevada →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →